Table 1.

Baseline characteristics for patients with SIRI ≤ 1.25 vs. SIRI>1.25 before and after propensity matching.

Clinical parameter	Unmatched (complete) dataset				Matched (1:1) dataset
	SIRI ≤ 1.25 (239)	SIRI>1.25 (202)	S.D	P	SIRI ≤ 1.25 (194)	SIRI > 1.25 (194)	S.D	P
Age				0.958				0.919
≤ 45	126	107	0.006		102	103	0.01
>45	113	95	0.006		92	91	0.01
Histological grade				0.115				0.287
G1	27	18	0.080		23	18	0.084
G2	124	90	0.127		93	83	0.103
G3	88	94	0.198		78	93	0.189
Tumor invasion depth				0.39				0.289
≤ 1/2	137	124	0.084		130	120	0.107
>1/2	102	78	0.084		64	74	0.107
Tumor size				0.546				0.759
≤ 4	137	110	0.056		107	110	0.030
>4	102	92	0.056		87	84	0.030
Lymphovascular invasion				0.020*				0.449
No	175	127	0.225		134	127	0.077
Yes	64	75	0.225		60	67	0.077
2018 FIGO stage				0.002*				0.155
IA	76	37	0.315		53	37	0.195
IB	121	112	0.096		99	109	0.104
IIA	42	53	0.209		42	48	0.073
Radiotherapy				0.002*				0.804
No	157	159	0.293		152	154	0.025
Yes	82	43	0.293		42	40	0.025
Chemoradiotherapy				0.085				0.484
No	205	184	0.167		174	178	0.073
Yes	34	18	0.167		20	16	0.073
NLR				<0.001*				<0.001*
≤ 2.8	169	64	0.848		130	64	0.723
>2.8	70	138	0.848		64	130	0.723
PLR				<0.001*				<0.001*
≤ 135	131	55	0.585		89	53	0.416
>135	108	147	0.585		105	141	0.416
MLR				<0.001*				<0.001*
≤ 0.29	187	82	0.830		165	80	1.02
>0.29	52	120	0.830		29	114	1.02

FIGO, International Federation of Gynecology and Obstetrics; SIRI, Systemic Inflammation Response Index; NLR, neutrophil lymphocyte ratio; PLR, platelet lymphocyte ratio; MLR: monocyte lymphocyte ratio; S.D, standardized difference.

^*Statistically significant (P < 0.05).